|
Market Cap (2-Jul) $147,983,008 (477th) |
Close (30-Jun) $0.99 |
Volume (30-Jun) 1,077,429 |
Shortsold (19-Jun) 1,473,254 (0.38%) (338th) |
|
52w High $0.66 |
52w Low $0.165 |
P/E - |
EPS -0.05 |
PAR released this announcement to the ASX on 31 October 2022, 7:57. The announcement is marked as price sensitive, and is 11 page(s) in length and 425.73kb in size.
You can view all announcements from PAR and see how they appear on a price chart on the announcements page.
At the date of this announcement, PAR was 0.976% short sold according to ASIC data. It was ranked the 234th most shorted stock on the ASX. It remains ranked 338th as of the latest reported data (19 June 2025).
| Other Recent Announcements from PAR | |
|---|---|
| Notification of cessation of securities - PAR | 29 June 2023, 16:43 |
| Primary and Secondary endpoints met in MPS I Trial | 6 June 2023, 12:28 |
| iPPS shows 3-year equivalent durability in OA Canine Study | 1 June 2023, 8:21 |
| Quarterly Activities/Appendix 4C Cash Flow Report | 31 October 2022, 7:57 |
| Notice of Annual General Meeting/Proxy Form | 28 October 2022, 13:06 |
| Paradigm Doses First UK Participant in Phase 3 Trial | 26 October 2022, 9:35 |
| PAR Reports Successful Primary Endpoint in Phase 2 Trial | 4 October 2022, 9:13 |
You must be logged in to post a reply.
Paradigm Biopharmaceuticals 